학술논문
EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma
Document Type
Abstract
Author
Source
In Value in Health June 2023 26(6) Supplement:S108-S108
Subject
Language
ISSN
1098-3015